COMMUNIQUÉS West-GlobeNewswire

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
11/03/2024
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today [...]
Novo Nordisk A/S - share repurchase programme
11/03/2024
Bagsværd, Denmark, 11 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
11/03/2024
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no detectable [...]
CenTrak Unveils the Industry’s First BLE Multi-Mode Platform for RTLS at HIMSS 2024
11/03/2024
Innovative RTLS Hardware Solution Offers Scalable Location Data Capabilities, Interoperability, and Cost-Effective Deployment NEWTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- CenTrak , the leader in real-time location [...]
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11/03/2024
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production [...]
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
11/03/2024
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 [...]
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
11/03/2024
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases
11/03/2024
Novel system features flexible tip to deliver flowable version of the Urinary Bladder Matrix (UBM) technology PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), [...]
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
11/03/2024
Company plans to initiate Phase 1 ACESOT-1051 ( A Multi- C enter E valuation of WEE1 Inhibitor in Patients with Advanced So lid T umors, APR- 1051 ) clinical trial evaluating , highly selective, oral WEE1 inhibitor, for [...]
NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant
11/03/2024
WILMINGTON, Del., March 11, 2024 (GLOBE NEWSWIRE) -- The U.S. Patent and Trademark Office has issued a patent, US11920140, for the use of CRISPR technologies to edit organellar genomes to NAPIGEN, Inc., a biotechnology [...]
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11/03/2024
Safety of ALX-001 Reinforced by New Data Presented at AD/PD™ 2024 Conference in Lisbon Two Oral Doses Selected for Further Study in Alzheimer’s and Parkinson’s Disease Patients NEW HAVEN, Conn., March 11, 2024 (GLOBE [...]
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
11/03/2024
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical responses achieved [...]
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
11/03/2024
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans [...]
Reviva to Present at the UBS Virtual CNS Day
11/03/2024
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
11/03/2024
ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high [...]
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth
11/03/2024
Kleem Chaudhary, Ph.D. appointed as President and Chief Executive Officer Dr. Chaudhary brings more than 20 years of leadership experience across multiple pharmaceutical and biotechnology companies LEXINGTON, Mass., [...]
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
11/03/2024
HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti [...]
Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding
11/03/2024
BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed [...]
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
11/03/2024
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase 1/2a clinical trial [...]

Pages